Novo confirms up-to-50% list-price cuts for Ozempic/Wegovy (effective Jan 2027)
Key Questions
What price cuts has Novo Nordisk confirmed for Ozempic and Wegovy?
Novo Nordisk has confirmed up to 50% list-price cut for Wegovy and 33% for Ozempic in the US, effective January 2027. These reductions aim to address wholesale pricing pressures amid the Inflation Reduction Act (IRA) and incoming generics.
When will the list-price cuts for Ozempic and Wegovy take effect?
The cuts are set to take effect in January 2027. This timing aligns with CEO statements on wholesale price adjustments and direct-to-consumer volume growth strategies.
What are the subscription prices for Wegovy?
Wegovy subscriptions are priced at $249-329 per month. An oral version is available for $149 per month through platforms like Ro, WW, LifeMD, Hims, and Sesame.
Which telehealth platforms offer discounted Wegovy subscriptions?
Platforms such as Ro, WW, LifeMD, Hims, and Sesame offer Wegovy subscriptions at $249-329/month and oral versions at $149/month. Hims & Hers is projected to see 45-50% expansion from this.
How many prescriptions have been written for oral GLP-1 medications?
Over 600,000 scripts have been written for oral GLP-1 medications. This reflects growing access through subscription models via telehealth providers.
What is the typical drop-off rate for GLP-1 users in the first year?
GLP-1 users experience a 10-20% drop-off rate in the first year. Reasons include challenges discussed by experts like Phenomix CEO Mark Bagnall on medication adherence and efficacy.
How is Novo Nordisk responding to market pressures like IRA and generics?
Novo's CEO highlighted wholesale price cuts and increased direct-to-consumer volume to counter IRA impacts and generic competition. Subscription plans for Wegovy aim to boost accessibility and market reach.
What impact have Wegovy subscriptions had on Hims & Hers stock?
Hims & Hers stock has spiked, with ETFs gaining attention, following rights to sell Ozempic and Wegovy partnerships. Analysts project 45-50% expansion for Hims amid the shift to branded GLP-1 drugs.
50% Wegovy/33% Ozempic US list cuts; Wegovy subs $249-329/mo/oral $149/mo via Ro/WW/LifeMD/Hims/Sesame (Hims +45-50% exp); 600k+ oral scripts; CEO wholesale cuts + DTC vol amid IRA/generics; GLP-1 drop-off 10-20% first year.